Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Objective: Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with pancreatic cancer (PC), but its value as a treatment biomarker is unclear. Summary Background Data: Although CA19-9 is an established prognostic marker for patients with PC, it is unclear how CA19-9 monitoring should be used to guide multimodality treatment and what level of change in CA19-9 constitutes a meaningful treatment response. Methods: CA19-9 measurements at diagnosis (pretx), after completion of all planned neoadjuvant therapy (preop), and after surgery (postop) were analyzed in patients with localized PC who had an elevated CA19-9 (≥35 U/dL) at diagnosis. Patients were classified by: 1) quartiles of pretx CA19-9 (Q1-4); 2) proportional changes in CA19-9 (ΔCA19-9) after the completion of neoadjuvant therapy; 3) normalization (CA19-9 <35 U/dL) of preop CA19-9; and 4) normalization of postop CA19-9. Results: Among 131 patients, the median overall survival (OS) was 30 months; 68 months for the 33 patients in Q1 of pretx CA19-9 (<80 U/dL) compared with 25 months for the 98 patients in Q2-4 (P = 0.03). For the 98 patients in Q2-4, preop CA19-9 declined (from pretx) in 86 (88%), but there was no association between the magnitude of ΔCA19-9 and OS (P = 0.77). Median OS of the 98 patients who did (n = 29) or did not (n = 69) normalize their preop CA19-9 were 46 and 23 months, respectively (P = 0.02). Of the 69 patients with an elevated preop CA19-9, 32 (46%) normalized their postop CA19-9. Failure to normalize preop or postop CA19-9 was associated with a 2.77-fold and 4.03-fold increased risk of death, respectively (P < 0.003) as compared with patients with normal preop CA19-9. Conclusions: Following neoadjuvant therapy, normalization of CA19-9, rather than the magnitude of change, is the strongest prognostic marker for long-term survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience
Winter, J. M., Cameron, J. L., Campbell, K. A., Arnold, M. A., Chang, D. C., Coleman, J., Hodgin, M. B., Sauter, P. K., Hruban, R. H., Riall, T. S., et al. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2006.08.018 · Cited by 1,489
Evans, D. B., Varadhachary, G. R., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Wang, H., Cleary, K. R., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8634 · Cited by 731 · cited 1×
“52 Charlson comorbidity index, median (IQR) 5 (2) 4 (1) 5 (1) 5 (3) 5 (2) 0.”
Self-citationFerrone, C. R., Finkelstein, D. M., Thayer, S. P., Muzikansky, A., Castillo, C. F.-D., & Warshaw, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3934 · Cited by 554 · cited 1×
“04 Borderline resectable 60 (46) 10 (30) 14 (42) 17 (52) 19 (59) Neoadjuvant therapy, n (%) Chemoradiation 40 (31) 16 (48) 11 (33) 8 (24) 5 (16) 0.”
Varadhachary, G. R., Wolff, R. A., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Abdalla, E., Wang, H., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8642 · Cited by 466 · cited 1×
“52 Charlson comorbidity index, median (IQR) 5 (2) 4 (1) 5 (1) 5 (3) 5 (2) 0.”
Self-citationRelationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A., Steplewski, Z., & Pour, P. M. (1987) · PubMed · Cited by 400
The prognostic and predictive value of serum CA19.9 in pancreatic cancer
Humphris, J. L., Chang, D. K., Johns, A. L., Scarlett, C. J., Pajic, M., Jones, M. D., Colvin, E. K., Nagrial, A., Chin, V. T., Chantrill, L. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr561 · Cited by 312 · cited 1×
“001 Age in years, median (IQR) 65 (12) 65 (13) 66 (11) 63 (10) 66 (12) 0.”
Hartwig, W., Strobel, O., Hinz, U., Fritz, S., Hackert, T., Roth, C., Büchler, M. W., & Werner, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2809-1 · Cited by 301
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294
Boone, B. A., Steve, J., Zenati, M. S., Hogg, M. E., Singhi, A. D., Bartlett, D. L., Zureikat, A. H., Bahary, N., & Zeh, H. J. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3842-z · Cited by 182
Vestergaard, E. M., Hein, H. O., Meyer, H., Grunnet, N., Jørgensen, J. B., Wolf, H., & Orntoft, T. F. (1999) · PubMed · Cited by 164
Cited by
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Lee, T., Teng, T. Z. J., & Shelat, V. G. (2020) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v12.i12.468 · Cited by 293
Metadata
- Authors
- Tsai, S., George, B., Wittmann, D., Ritch, P. S., Krepline, A. N., Aldakkak, M., Barnes, C. A., Christians, K. K., Dua, K., Griffin, M., Hagen, C., Hall, W. A., Erickson, B. A., & Evans, D. B.
- Venue
- Annals of Surgery
- Published
- 2020-04
- Volume
- 271
- Issue
- 4
- Pages
- 740-747
- ISSN
- 0003-4932 (ISSN-L)
- 1528-1140
- OpenAlex
- W2897709693
- Cited by
- 222
- References
- 20
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. https://app.cochat.ai/papers/10.1097/sla.0000000000003049
- The paper
- Tsai, S., George, B., Wittmann, D., Ritch, P. S., Krepline, A. N., Aldakkak, M., Barnes, C. A., Christians, K. K., Dua, K., Griffin, M., Hagen, C., Hall, W. A., Erickson, B. A., & Evans, D. B. (2020). Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Annals of Surgery. https://doi.org/10.1097/sla.0000000000003049
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.